Management of anticoagulation in patients with metastatic castration–resistant prostate cancer receiving abiraterone + prednisone

Abstract

Monitor INR 3 days after initiation and then once weekly for 4 weeks, as INR becomes stable the interval may increased slowly.Figure 1.0. Anticoagulation management for atrial fibrillation in a patient receiving abiraterone + prednisone. Abbreviations: CAD; coronary artery disease. ASA; acetylsalicylic acid. CHADS 2 ; congestive heart failure, hypertension, age >65, diabetes, prior stroke or transient attack. CrCl; creatinine clearance. INR; international normalized ratio. * -Close monitoring of INR Abbreviations: ASA, acetylsalicylic acid; CAD; coronary artery disease. CHADS 2 , Congestive heart failure, hypertension, age, diabetes, prior stroke or transient attack; LMWH, low-molecular weight heparin. Table 2.0. Recommended management strategies for anticoagulation in patients receiving abiraterone + prednisone. References Ŧ Dose adjust for renal function and body weight * -Dose adjust for renal function; not recommended if CrCl < 30 ml/min ** -Monitor INR 3 days after initiation and then once weekly for 4 weeks, as INR becomes stable the interval may be increased slowly.

Current thromboprophylaxis in urological cancer patients during COVID pandemic

“…The vast majority of scientific research concerns patients with hormone- and chemotherapy. [ 27 , 32 , 33 , 34 ]. Significant impact on risk factors has the presents of metastases.…”

A new method to quantify the effect of co-medication on the efficacy of abiraterone in metastatic castration-resistant prostate cancer patients

“…The IDS varied in a wide range and after dichotomization the high IDS proved to predict a significantly longer AA treatment and OS compared to the low IDS. In case of patients treated with AA, the IDS is a mirror of DDI, which was the main subject of some reports ( Graff and Beer, 2014 ; Benoist et al, 2016 ; Jamani et al, 2016 ; Bonnet et al, 2017 ; Del Re et al, 2017 ; Dubinsky et al, 2019 ; Escudero-Vilaplana et al, 2020 ; Vicente-Valor et al, 2021 ). However, none of these studies analyzed the impact of DDI on the outcome of AA treatment.…”

“…The occurrence of tamsulosin and tramadol in our case has been described above, while the frequency of duloxetine was 1%. The other publications ( Graff and Beer, 2014 ; Benoist et al, 2016 ; Del Re et al, 2017 ; Dubinsky et al, 2019 ) evaluated the potential DDI based on theoretical considerations from the literature. A list of drugs was given with different grades of DDI ( Del Re et al, 2017 ) (drugs not present in our study are in italics and the DS is indicated for other drugs): increased DDI [amiodarone (DS = 23), flecainide , hydrocodone and propafenone (13)] or moderate (amitriptyline (16), aripiprazole , carbamazepine (−5), carvedilol (8), codeine (2.5), donepezil , duloxetine (13), fluoxetine , fosamprenavir , galantamine , metoprolol (7), mexiletine , nicardipine , oxycodone (5), pioglitazone , propranolol , paroxetine (16), pimozide , risperidone , ritonavir , trazodone and venlafaxine (8)].…”

“…The grouping is mostly in line with our DS values, but duloxetine and paroxetine could be placed in the “increased” DDI group. The management of anticoagulation in mCRPC patients treated with AA+prednisolone ( Dubinsky et al, 2019 ) was discussed with the emphasis of interactions of AA with warfarin (DS = 13), rivaroxaban (2), endoxaban (0), apixaban (10), dabigatran (0), and low-molecular-weight heparin (1).…”